The Longevity Industry
Billions are flowing into research that promises to add decades to the human lifespan. The science is more serious than the hype — and more uncertain than the investors admit.
Bryan Johnson is 47 years old and spends approximately $2 million annually attempting to reverse that fact. His "Blueprint" protocol — documented obsessively on his website and social media — involves over 100 daily supplements, a precisely calibrated 1,977-calorie diet administered by algorithm, a strict 8:30 p.m. bedtime, and a battery of medical tests that would be excessive even for a seriously ill patient. His stated goal is to achieve the biological age profile of an 18-year-old. His most recent biological age measurements, by various assays, range from the high thirties to the low forties. He has achieved, at enormous expense and effort, a result that is probably attainable for most health-conscious people through exercise, diet, and adequate sleep.
Johnson is not a fraud. He is something more interesting: a serious person who has become the public face of an industry that is simultaneously doing important science and selling that science ahead of what the evidence justifies. Understanding the difference between what the longevity industry knows and what it claims to know requires more careful attention than either the enthusiasts or the debunkers are currently providing.
What aging research has actually established
The biology of aging has advanced remarkably in the past two decades. Research beginning with Cynthia Kenyon's discovery in 1993 that a single gene mutation could double the lifespan of C. elegans opened a field that has since identified dozens of conserved aging pathways in organisms from yeast to primates.
The most robustly studied mechanisms include: the mTOR pathway, which regulates cellular growth and is inhibited by rapamycin; the sirtuin pathways, which regulate cellular stress response and are activated by NAD+ precursors; the AMPK pathway, activated by caloric restriction and metformin; and cellular senescence, the accumulation of "zombie cells" that have stopped dividing but remain metabolically active and secreting inflammatory compounds.
Each of these pathways has produced genuine results in animal models. Rapamycin reliably extends lifespan in mice by 10 to 25 percent when administered in middle age. Senolytic drugs — compounds that selectively clear senescent cells — reduce markers of age-related disease in mice and are now in Phase 2 human trials. Caloric restriction extends lifespan in every organism in which it has been tested, from yeast to non-human primates.
The translation from mice to humans has been, as it almost always is, more difficult than the animal data suggested. Human trials of the most promising compounds are ongoing, but the longevity field faces a fundamental methodological problem: the gold standard endpoint — human lifespan — cannot be measured in a trial with any reasonable duration. Researchers have therefore focused on biomarkers of aging — measures of biological age derived from methylation patterns, inflammatory markers, telomere length, and other proxies — but the relationship between these biomarkers and actual longevity in humans remains incompletely validated.
Metaculus maintains a forecast on whether a drug or intervention will be demonstrated to extend median human lifespan by more than 5 years in a randomized controlled trial with at least 10,000 participants before 2040. The median forecast is 12 percent probability. This is not a statement that longevity research is failing — it is a statement about how long the science requires.
The rapamycin question
Of all the compounds in the longevity toolkit, rapamycin — an immunosuppressant drug approved in 1999 for organ transplant recipients — has generated the most serious scientific interest and the most active off-label use.
The evidence in mice is compelling: a 2009 study in Nature found that rapamycin extended lifespan in mice by 9 to 14 percent even when administration began at 20 months (roughly equivalent to 60 years in humans). Subsequent research has identified mechanisms — mTOR inhibition reduces cellular "growth mode" signaling that appears to accelerate aging-associated pathways.
The evidence in humans is limited but intriguing. The TRIIM trial, which administered rapamycin to a small cohort of healthy older adults, found reversal of immunological aging markers; the more recent AgeMeter trial is attempting to replicate and extend this finding. The PEARL trial, run by the Ora Biomedical longevity company, is the largest randomized trial of low-dose rapamycin in healthy adults currently underway, with results expected in late 2026. Kalshi has a contract on whether PEARL's results will show statistically significant improvement in at least one longevity biomarker; it was trading at 61 percent in January 2026.
The practical question for the many people who are already taking rapamycin off-label — a practice that has become common enough among technology-adjacent professionals in San Francisco to generate genuine clinical concern — is whether the known risks justify the uncertain benefits. Rapamycin is an immunosuppressant; chronic use raises infection risk, impairs wound healing, and may have metabolic effects including insulin resistance. In the doses used by longevity self-experimenters (typically 2-6 mg weekly, far below transplant doses), these risks are probably modest. But "probably modest" is not the same as "established safe," and the people taking the drug are not in monitored trials where adverse effects would be systematically documented.
The NAD+ economy
The most commercially successful segment of the longevity industry is also the one with the thinnest evidence base: the NAD+ precursor supplements. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are sold by dozens of companies — including David Sinclair's Elysium Health and Andrew Marantz's Tru Niagen — on the basis that raising cellular NAD+ levels will activate sirtuin pathways associated with longevity in animal models.
The animal data is real: NAD+ precursors do extend healthy lifespan in mice in some studies, and sirtuin activation does appear to mimic certain aspects of caloric restriction at the molecular level. The human data is where the story becomes more complicated.
Human trials of NR and NMN have consistently shown that oral supplementation does raise blood NAD+ levels. What they have not consistently shown is that this increase translates into improved function on any clinically meaningful measure. A 2023 meta-analysis of 11 randomized controlled trials of NAD+ precursors found no statistically significant effect on muscle strength, cognitive function, metabolic markers, or any other primary endpoint. The supplements raise a number that serves as a proxy for something, but whether raising that proxy actually produces the benefits observed in animal models remains undemonstrated.
This does not make NAD+ precursors fraudulent. It makes them a bet on a scientific hypothesis that has not yet been confirmed in humans. At $50 to $150 per month, it is a bet that millions of people are apparently willing to make. The industry has grown to approximately $800 million in annual revenue in the United States alone.
What we should want from longevity science
The most important contribution that longevity research could make is not the extension of maximum human lifespan — pushing past the current apparent ceiling of around 115 to 125 years — but the compression of morbidity: the reduction of the years spent in disability and decline at the end of life.
This goal is less glamorous than the prospect of living to 150, but it is both more achievable and more important for human welfare. The diseases of aging — cardiovascular disease, cancer, neurodegenerative diseases, type 2 diabetes — are not merely unpleasant endings. They consume an extraordinary share of healthcare resources, reduce productivity and social contribution during the years preceding death, and inflict suffering that is preventable given adequate scientific progress.
The GLP-1 story (which we have covered in a companion piece) offers a useful template: a class of drugs developed for one indication that turns out to address a fundamental dysregulation underlying multiple conditions. The longevity field's most serious researchers are looking for similar leverage points — interventions that address aging itself rather than its individual disease manifestations.
Whether they will find them in time to matter for the people currently funding the search is a genuinely open question. Metaculus forecasts a 38 percent probability of a demonstrated 10-year lifespan extension in non-human primates before 2035 — progress that would substantially validate the animal-to-human translation hypothesis. The investors who are funding longevity research at scale are, in effect, betting at much higher odds than that.
Whether those odds are warranted is something only time, and carefully conducted science, will determine.
Dr. Amara Singh is a staff writer at The Auguro covering medicine, science, and public health.